We are live on ! Find out more
VBIO

Valion Bio
VBIO

3 hedge funds and large institutions have $31.7K invested in Valion Bio in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.62% more ownership

Funds ownership: 0.62% → 1.24% (+0.62%)

63% less funds holding

Funds holding: 8 → 3 (-5)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

67% less capital invested

Capital invested by funds: $96.3K → $31.7K (-$64.7K)

Holders
3
Holders Change
-5
Holders Change %
-62.5%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$72.1K
2
Citigroup
Citigroup
New York
+$3.7K
3
TRCT
Tower Research Capital (TRC)
New York
+$1.85K

Top Sellers

Rank Fund Capital Flow
1
SSWM
Sheets Smith Wealth Management
North Carolina
-$63.8K
2
TSS
Two Sigma Securities
New York
-$10.3K
3
BFM
Boothbay Fund Management
New York
-$3.62K
4
Millennium Management
Millennium Management
New York
-$3.2K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.09K

VBIO Hedge Fund Activity: Q3 2023 in Review

3 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q3 2023, worth a combined $31.7K — down 67% from $96.3K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of VBIO and 3 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $72.1K. The largest seller was Sheets Smith Wealth Management, exiting entirely with an estimated $63.8K sold.

  • 3 institutional investors held Valion Bio (VBIO) as of Q3 2023, down from 8 in Q2 2023.
  • Funds reported $31.7K of Valion Bio stock for Q3 2023, down 67% quarter-over-quarter.
  • 3 funds opened new Valion Bio positions in Q3 2023 and 8 closed out, a net change of -5 holders.
  • The largest Valion Bio buyer in Q3 2023 was Citadel Advisors, an estimated $72.1K added.
  • The largest Valion Bio seller in Q3 2023 was Sheets Smith Wealth Management, an estimated $63.8K sold.

Based on aggregated 13F filings for Q3 2023.